Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study
Background/Aims: To assess the antiviral efficacy of lamivudine (LAM), entecavir (ETV), telbivudine (LDT), and lamivudine and adefovir dipivoxil (CLA) combination in previously untreated hepatitis B patients at different time points during a 52-week treatment period. Patients and Methods: A total of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
| Series: | The Saudi Journal of Gastroenterology |
| Subjects: | |
| Online Access: | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2014;volume=20;issue=6;spage=350;epage=355;aulast=Yu |
| _version_ | 1818542823020953600 |
|---|---|
| author | Shu Yu Qin Zhou Xiao Miao Zhao Min Yuan Chang Tai Wang Xiao Guang Cheng Zhen Hua Zhang Xu Li |
| author_facet | Shu Yu Qin Zhou Xiao Miao Zhao Min Yuan Chang Tai Wang Xiao Guang Cheng Zhen Hua Zhang Xu Li |
| author_sort | Shu Yu |
| collection | DOAJ |
| description | Background/Aims: To assess the antiviral efficacy of lamivudine (LAM), entecavir (ETV), telbivudine (LDT), and lamivudine and adefovir dipivoxil (CLA) combination in previously untreated hepatitis B patients at different time points during a 52-week treatment period. Patients and Methods: A total of 164 patients were included in this prospective, open-label, head-to-head study. Serum levels of alanine transaminase (ALT), hepatitis B virus (HBV) DNA, and hepatitis B e antigen (HBeAg) were measured at baseline, and at 12, 24, and 52 weeks of treatment. Results: Median reductions in serum HBV DNA levels at 52 weeks (log 10 copies/mL) were as follows: LAM, 3.98; ETV, 3.89; LDT, 4.11; and CLA, 3.36. The corresponding HBV DNA undetectability rates were 83%, 96%, 91%, and 89%, respectively. These two measures showed no significant intergroup differences. Clinical efficacy appeared related to HBV DNA level reduction after 24 weeks of therapy. Patients were divided into three groups based on HBV DNA levels at week 24: Undetectable (<10 3 copies/mL), detectable but <10 4 copies/mL, and >10 4 copies/mL. Patients with levels below quantitation limit (QL) were analyzed at 52 weeks for HBV DNA undetectability rate (94%), ALT normalization rate (83%), and viral breakthrough rate (0%). The corresponding values in the QL-10 4 copies/mL group were 50%, 75%, and 13%, whereas those in the above 10 4 copies/mL group were 53%, 65%, and 18%. There were significant differences at week 52 for HBV DNA levels and viral breakthrough rate between the three groups. Conclusions: Different nucleos(t)ide (NUC) analogues tested exhibited no significant differences in effectiveness for Chinese NUC-naive HBV patients during 1-year treatment period. |
| first_indexed | 2024-12-11T22:27:12Z |
| format | Article |
| id | doaj.art-e7888634ce124911b61e31f565077361 |
| institution | Directory Open Access Journal |
| issn | 1319-3767 1998-4049 |
| language | English |
| last_indexed | 2024-12-11T22:27:12Z |
| publishDate | 2014-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | The Saudi Journal of Gastroenterology |
| spelling | doaj.art-e7888634ce124911b61e31f5650773612022-12-22T00:48:15ZengWolters Kluwer Medknow PublicationsThe Saudi Journal of Gastroenterology1319-37671998-40492014-01-0120635035510.4103/1319-3767.145320Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head studyShu YuQin ZhouXiao Miao ZhaoMin YuanChang Tai WangXiao Guang ChengZhen Hua ZhangXu LiBackground/Aims: To assess the antiviral efficacy of lamivudine (LAM), entecavir (ETV), telbivudine (LDT), and lamivudine and adefovir dipivoxil (CLA) combination in previously untreated hepatitis B patients at different time points during a 52-week treatment period. Patients and Methods: A total of 164 patients were included in this prospective, open-label, head-to-head study. Serum levels of alanine transaminase (ALT), hepatitis B virus (HBV) DNA, and hepatitis B e antigen (HBeAg) were measured at baseline, and at 12, 24, and 52 weeks of treatment. Results: Median reductions in serum HBV DNA levels at 52 weeks (log 10 copies/mL) were as follows: LAM, 3.98; ETV, 3.89; LDT, 4.11; and CLA, 3.36. The corresponding HBV DNA undetectability rates were 83%, 96%, 91%, and 89%, respectively. These two measures showed no significant intergroup differences. Clinical efficacy appeared related to HBV DNA level reduction after 24 weeks of therapy. Patients were divided into three groups based on HBV DNA levels at week 24: Undetectable (<10 3 copies/mL), detectable but <10 4 copies/mL, and >10 4 copies/mL. Patients with levels below quantitation limit (QL) were analyzed at 52 weeks for HBV DNA undetectability rate (94%), ALT normalization rate (83%), and viral breakthrough rate (0%). The corresponding values in the QL-10 4 copies/mL group were 50%, 75%, and 13%, whereas those in the above 10 4 copies/mL group were 53%, 65%, and 18%. There were significant differences at week 52 for HBV DNA levels and viral breakthrough rate between the three groups. Conclusions: Different nucleos(t)ide (NUC) analogues tested exhibited no significant differences in effectiveness for Chinese NUC-naive HBV patients during 1-year treatment period.http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2014;volume=20;issue=6;spage=350;epage=355;aulast=YuAdefovir dipivoxilantiviral therapychronic hepatitis Bentecavirlamivudinetelbivudine |
| spellingShingle | Shu Yu Qin Zhou Xiao Miao Zhao Min Yuan Chang Tai Wang Xiao Guang Cheng Zhen Hua Zhang Xu Li Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study The Saudi Journal of Gastroenterology Adefovir dipivoxil antiviral therapy chronic hepatitis B entecavir lamivudine telbivudine |
| title | Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study |
| title_full | Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study |
| title_fullStr | Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study |
| title_full_unstemmed | Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study |
| title_short | Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study |
| title_sort | comparison of the antiviral effects of different nucleos t ide analogues in chinese patients with chronic hepatitis b a head to head study |
| topic | Adefovir dipivoxil antiviral therapy chronic hepatitis B entecavir lamivudine telbivudine |
| url | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2014;volume=20;issue=6;spage=350;epage=355;aulast=Yu |
| work_keys_str_mv | AT shuyu comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT qinzhou comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT xiaomiaozhao comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT minyuan comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT changtaiwang comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT xiaoguangcheng comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT zhenhuazhang comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy AT xuli comparisonoftheantiviraleffectsofdifferentnucleostideanaloguesinchinesepatientswithchronichepatitisbaheadtoheadstudy |